Silja Groner

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Thorsten Zenz, Sonja Häbe, Tina Denzel et al. · Blood · 2009 · 285 citations · Full text

Medicine, Molecular Genetics, Oncology +15

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

Stephan Stilgenbauer, Thorsten Zenz, Dirk Winkler et al. · Journal of Clinical Oncology · 2009 · 270 citations · Full text

Medicine, Oncology, Pharmacology +17

Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome

Sabine Käyser, Richard F. Schlenk, Martina Correa Londoño et al. · Blood · 2009 · 269 citations · Full text

Medicine, Genetics, Oncology +14

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

Richard F. Schlenk, Konstanze Döhner, Michael Kneba et al. · Haematologica · 2008 · 209 citations · Full text

Medicine, Molecular Genetics, Oncology +13

Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia

Maria Teresa Voso, Stefan Hohaus, Francesco Guidi et al. · Leukemia · 2008 · 37 citations

Medicine, Genetics, Hematology +14